San Diego based biotech company Ambrx and MabSpace Biosciences, a biotechnology company focusing on discovery and development antibody therapeutics using its immune tolerance breaking technology (IMBT) based antibody discovery platform and translational sciences capability, early today confirmed that the two companies have agreed to collaborate on discovery and development of multiple novel antibody-drug conjugates or ADCs in China and around the world.

According to the agreement, MabSpace, based in Suzhou, a major city located in southeastern Jiangsu Province of East China, about 100 km (62 mi) northwest of Shanghai, will employ its proprietary immune tolerance breaking technology to generate and identify humanized antibodies suitable for the development of ADCs. In turn and Ambrx will employ its EuCode based site-specific conjugation technology to develop lead ADC molecules. Under the terms of the agreement, both companies will jointly develop and share the cost and rights of the resulting ADC products.

“This collaboration [with MabSpace] can potentially enhance our site specific protein conjugation technology platform capabilities,” noted Alex Qiao, Ph.D, CEO of Ambrx.


“MabSpace’s unique immune tolerance breaking-based antibody discovery platform and its ability to obtain antibodies with diverse epitopes is well suited for the development of ADC and therapeutic applications. The collaboration with Ambrx is our third deal with established biopharma companies for antibody based therapeutics development with our immune tolerance breaking technology,” said Xueming Qian, Ph.D, Chairman and CEO of MabSpace Biosciences.

Non conventional conjugation
Ambrx develops breakthrough protein therapeutics using an expanded genetic code. Unlike conventional conjugation techniques that create a mixture of suboptimal molecules, the company’s technology combines site specific conjugation with proprietary linkers, payloads and pharmacokinetic extenders to create a sing molecular species that is optimized for safety, efficacy and biophysical properties. Using their proprietary technology, dubbed Protein Medicinal Chemistry™, researchers at Ambrx can optimize any protein or antibody to create potentially best-in-class therapeutics such as long-acting proteins, bi-specifics and antibody drug conjugates.